Menu Search
Equities

Valneva SE

  • Add to watchlist
  • Add to portfolio
  • Add an alert
VALN:NSQ

Valneva SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.68
  • Today's Change0.189 / 1.99%
  • Shares traded5.22k
  • 1 Year change+49.60%
  • Beta1.8160
Data delayed at least 15 minutes, as of Feb 09 2026 20:16 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy2
Outperform1
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 4 analysts offering 12 month price targets for Valneva SE (ADR) have a median target of 13.01, with a high estimate of 18.02 and a low estimate of 6.85. The median estimate represents a 37.10% increase from the last price of 9.49.
High89.9%18.02
Med37.1%13.01
Low-27.8%6.85

Earnings history & estimates in EUR

On Nov 20, 2025, Valneva SE (ADR) reported 3rd quarter 2025 losses of -0.52 per share.
The next earnings announcement is expected on Mar 23, 2026.
Average growth rate-117.31%
Valneva SE (ADR) reported annual 2024 losses of -0.16 per share on Mar 20, 2025.
Average growth rate+29.54%
More ▼

Revenue history & estimates in EUR

Valneva SE (ADR) had 3rd quarter 2025 revenues of 29.44m. This missed the 42.08m consensus estimate of the 4 analysts following the company. This was 10.12% below the prior year's 3rd quarter results.
Average growth rate-8.08%
Valneva SE (ADR) had revenues for the full year 2024 of 169.58m. This was 10.32% above the prior year's results.
Average growth rate-14.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.